Advertisement

Quality of Life Research

, Volume 15, Issue 6, pp 941–949 | Cite as

Impacts of HIV infection and HAART use on quality of life

  • Chenglong Liu
  • David Ostrow
  • Roger Detels
  • Zheng Hu
  • Lisette Johnson
  • Lawrence Kingsley
  • Lisa P. Jacobson
Article

Abstract

Background: Studies have shown the detrimental effect of HIV disease on quality of life (QOL). Changes in QOL related to the use of highly active antiretroviral therapy (HAART) have been inconsistent and it is unknown how QOL after HAART compares to pre-infection levels. Objective: The objective of this study was to determine the impacts of becoming HIV infected and using HAART on QOL within individuals followed in the Multicenter AIDS Cohort Study (MACS). Methods: Using the standard Medical Outcome Study SF-36 form, QOL data were collected pre-seroconversion, post-seroconversion but before HAART initiation, and after HAART initiation for 68 seroconverters. The QOL physical health summary score (PHS) and mental health summary score (MHS) were used as outcomes. The effects of HIV infection and HAART use on QOL summary scores were determined using random effects mixed linear models after controlling for possible confounders. The clinical significance of QOL change was assessed using the Cohen’s effect size method. Results: Compared to pre-seroconversion values, the PHS decreased after seroconversion (mean difference (diff) = −1.62; 95% confidence interval (CI): [−3.20, −0.03]) and after HAART initiation (diff = −4.20; 95% CI: [−5.86, −2.54]) with small to medium effect sizes. The score remained significantly lower than prior to HIV infection (diff = −6.16; 95% CI: [−8.09, −4.23]) after being on HAART for more than 4 years. The MHS did not significantly differ upon seroconversion (diff = −1.16; 95% CI: [−3.32, 1.00]). After using HAART for more than 4 years, the MHS was significantly greater than prior to HIV infection (diff = 2.93; 95% CI: [0.31, 5.55]) with a small effect size. Conclusion: The QOL of participants has been dynamic over the HIV disease course. HIV infection deteriorated physical but not mental QOL. In this group, although the PHS following HAART has remained lower than that prior to infection, HAART has enhanced mental health functioning.

Keywords

HAART HIV infection Multicenter AIDS Cohort Study Quality of life 

Abbreviations

ART

antiretroviral therapy

CESD

Center for Epidemiological Studies Depression scale

CI

confidence interval

Diff

difference

HAART

highly active antiretroviral therapy

HIV

human immunodeficiency virus

MACS

Multicenter AIDS Cohort Study

MHS

mental health summary score

NNRTI

non-nucleoside reverse transcriptase inhibitor

NRTI

nucleoside reverse transcriptase inhibitor

PHS

physical health summary score

PI

protease inhibitor

QOL

quality of life

SF-36

short form-36

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wu, AW, Mathews, WC, Brysk, LT,  et al. 1990Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complexJ Acquir Immune Defic Syndr3683690PubMedGoogle Scholar
  2. 2.
    Hays, RD, Cunningham, WE, Sherbourne, CD,  et al. 2000Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV Cost and Services Utilization StudyAm J Med108714722PubMedCrossRefGoogle Scholar
  3. 3.
    Wu, AW, Rubin, HR, Mathews, WC,  et al. 1991A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infectionMed Care29786798PubMedGoogle Scholar
  4. 4.
    Burgess, A, Dayer, M, Catalan, J, Hawkins, D, Gazzard, B 1993The reliability and validity of two HIV-specific health-related Quality-of-Life measures: A preliminary analysisAIDS710011008PubMedGoogle Scholar
  5. 5.
    Fischl, MA, Richman, DD, Grieco, MH,  et al. 1987The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trialN Engl J Med317185191PubMedCrossRefGoogle Scholar
  6. 6.
    Lenderking, WR, Gelber, RD, Cotton, DJ,  et al. 1994Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials GroupN Engl J Med330738743PubMedCrossRefGoogle Scholar
  7. 7.
    Hammer, SM, Squires, KE, Hughes, MD,  et al. 1997A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study TeamN Engl J Med337725733PubMedCrossRefGoogle Scholar
  8. 8.
    Detels, R, Munoz, A, McFarlane, G,  et al. 1998Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study InvestigatorsJAMA28014971503PubMedCrossRefGoogle Scholar
  9. 9.
    Low-Beer, S, Chan, K, Wood, E,  et al. 2000Health related quality of life among persons with HIV after the use of protease inhibitorsQual Life Res9941949PubMedCrossRefGoogle Scholar
  10. 10.
    Saunders, DS, Burgoyne, RW 2002Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART eraInt J STD AIDS13683690PubMedCrossRefGoogle Scholar
  11. 11.
    Carrieri, P, Spire, B, Duran, S,  et al. 2003Health-related quality of life after 1 year of highly active antiretroviral therapyJ Acquir Immune Defic Syndr323847PubMedGoogle Scholar
  12. 12.
    Nieuwkerk, PT, Gisolf, EH, Colebunders, R, Wu, AW, Danner, SA, Sprangers, MA 2000Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study GroupAIDS14181187PubMedCrossRefGoogle Scholar
  13. 13.
    Gill, CJ, Griffith, JL, Jacobson, D, Skinner, S, Gorbach, SL, Wilson, IB 2002Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of lifeJ Acquir Immune Defic Syndr30485492PubMedGoogle Scholar
  14. 14.
    Kaslow, RA, Ostrow, DG, Detels, R, Phair, JP, Polk, BF, Rinaldo, CR,Jr. 1987The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participantsAm J Epidemiol126310318PubMedGoogle Scholar
  15. 15.
    Detels, R, Phair, JP, Saah, AJ,  et al. 1992Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort StudyJ Epidemiol [Jpn]2s11s19Google Scholar
  16. 16.
    Giorgi, JV, Cheng, HL, Margolick, JB,  et al. 1990Quality control in the flow cytometric measurement of T-lymphocyte subsets: The multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study GroupClin Immunol Immunopathol55173186PubMedCrossRefGoogle Scholar
  17. 17.
    Radloff, LS 1977The CES-D scale: A self-report depression scale for research in the general populationAppl Psychol Meas1385401Google Scholar
  18. 18.
    Breslan, N 1984Depressive symptoms, major depression, and generalized anxiety: A comparison of self-reports on CES-D and results from diagnostic interviewsPsychiatry Res15219229CrossRefGoogle Scholar
  19. 19.
    Kantz, ME, Harris, WJ, Levitsky, K, Ware, JE,Jr., Davies, AR 1992Methods for assessing condition-specific and generic functional status outcomes after total knee replacementMed Care30MS240MS252PubMedGoogle Scholar
  20. 20.
    McHorney, CA, Ware, JE,Jr., Lu, JF, Sherbourne, CD 1994The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groupsMed Care324066PubMedGoogle Scholar
  21. 21.
    Ware, JE,Jr., Kosinski, M, Bayliss, MS, McHorney, CA, Rogers, WH, Raczek, A 1995Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes StudyMed Care33AS264AS279PubMedGoogle Scholar
  22. 22.
    Ware, JE, Kosinski, M 2001Interpreting SF-36 summary health measures: A responseQual Life Res10405413PubMedCrossRefGoogle Scholar
  23. 23.
    DHHS/Henry J. Kaiser, Family Foundation Panel on Clinical ractices for the Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. April 2005 revision. Available at http://aidsinfo.nih.gov. 2005
  24. 24.
    Li, X, Margolick, JB, Conover, CS,  et al. 2005Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort studyJ Acquir Immune Defic Syndr38320328PubMedGoogle Scholar
  25. 25.
    Piette, J, Wachtel, TJ, Mor, V, Mayer, K 1995The impact of age on the quality of life in persons with HIV infectionJ Aging Health7163178PubMedGoogle Scholar
  26. 26.
    Bing, EG, Hays, RD, Jacobson, LP,  et al. 2000Health-related quality of life among people with HIV disease: Results from the Multicenter AIDS Cohort StudyQual Life Res95563PubMedCrossRefGoogle Scholar
  27. 27.
    Miners, AH, Sabin, CA, Mocroft, A, Youle, M, Fisher, M, Johnson, M 2001Health-related quality of life in individuals infected with HIV in the era of HAARTHIV Clin Trials2484492PubMedCrossRefGoogle Scholar
  28. 28.
    Ahdieh, L, Gange, SJ, Greenblatt, R,  et al. 2000Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virusAm J Epidemiol152923933PubMedCrossRefGoogle Scholar
  29. 29.
    Yamashita, TE, Phair, JP, Munoz, A,  et al. 2001Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort StudyAIDS15735746PubMedCrossRefGoogle Scholar
  30. 30.
    Cohen, J. 1969Statistical Power Analysis for the Behavioural SciencesAcademic PressLondonGoogle Scholar
  31. 31.
    Rosenbaum, PR, Rubin, DB 1983The central role of the propensity score in observational studies for causal effectsBiometrika704155CrossRefGoogle Scholar
  32. 32.
    Norman, GR, Sloan, JA, Wyrwich, KW 2003Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviationMed Care41582592PubMedCrossRefGoogle Scholar
  33. 33.
    Cohen, C, Revicki, DA, Nabulsi, A, Sarocco, PW, Jiang, P 1998A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study GroupAIDS1214951502PubMedCrossRefGoogle Scholar
  34. 34.
    Revicki, DA, Swartz, C, Wu, AW, Haubrich, R, Collier, AC 1999Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3 Antivir Ther43544PubMedGoogle Scholar
  35. 35.
    Arpinelli, F, Visona, G, Bruno, R, De, CG, Apolone, G 2000Health-related quality of life in asymptomatic patients with HIV. Evaluation of the SF-36 health survey in Italian patientsPharmacoeconomics186372PubMedCrossRefGoogle Scholar
  36. 36.
    Ostrow, DE, Fox, KJ, Chmiel, JS,  et al. 2002Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual menAIDS16775780PubMedCrossRefGoogle Scholar
  37. 37.
    Weinfurt, KP, Willke, RJ, Glick, HA, Freimuth, WW, Schulman, KA 2000Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patientsMed Care38404410PubMedCrossRefGoogle Scholar
  38. 38.
    Call, SA, Klapow, JC, Stewart, KE,  et al. 2000Health-related quality of life and virologic outcomes in an HIV clinicQual Life Res9977985PubMedCrossRefGoogle Scholar
  39. 39.
    Dukers, NH, Spaargaren, J, Geskus, RB, Beijnen, J, Coutinho, RA, Fennema, HS 2002HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: Using a novel approach for detecting recent infectionsAIDS16F19F24PubMedCrossRefGoogle Scholar
  40. 40.
    Samsa, G, Edelman, D, Rothman, ML, Williams, GR, Lipscomb, J, Matchar, D 1999Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark IIPharmacoeconomics15141155PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Chenglong Liu
    • 1
  • David Ostrow
    • 2
  • Roger Detels
    • 3
  • Zheng Hu
    • 1
  • Lisette Johnson
    • 1
  • Lawrence Kingsley
    • 4
  • Lisa P. Jacobson
    • 1
  1. 1.E7139 Bloomberg School of Public HealthJohns Hopkins UniversityBaltimoreUSA
  2. 2.Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  3. 3.School of Public HealthUniversity of CaliforniaLos AngelesUSA
  4. 4.Graduate School of Public HealthUniversity of PittsburghPittsburgUSA

Personalised recommendations